Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/13/2025 | $10.00 | Buy | H.C. Wainwright |
| 3/7/2025 | $15.00 | Sector Outperform | Scotiabank |
| 11/25/2024 | $24.00 → $5.00 | Buy → Neutral | BofA Securities |
| 10/24/2024 | $20.00 | Buy | UBS |
| 10/1/2024 | $25.00 | Outperform | Wedbush |
| 9/25/2024 | $21.00 | Buy | Truist |
| 7/25/2024 | $24.00 | Buy | BofA Securities |
| 5/9/2024 | Overweight | Cantor Fitzgerald |
First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab[212Pb]VMT01 3.0 mCi single agent dose Cohort re-opened SEATTLE, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted alpha-particle therapy (TAT), in patients with previously treated, histologically confirmed metastatic melanoma and positive melanocortin 1 receptor (MC1R) imaging scans. Patients in this cohort are recei
SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company's Chief Financial Officer, effective today. Mr. Sendek brings extensive experience in senior corporate roles in biotech finance and as a highly respected senior equity research analyst at a number of leading firms. Mr. Sendek previously served as CFO at four biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. He has a successful track record in corporate finance, having completed
SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that its Board of Directors has appointed Maya Martinez-Davis as an independent director to the Company's Board of Directors, effective today. Ms. Martinez-Davis currently serves as President of GSK's U.S. Commercial business, a position she has held since September 2019. In that role, she leads a robust and complex business portfolio of products in specialty, respiratory, oncology and vaccines. Prior to GSK, Ms. Martinez-Davis was President of biopharma Latin
H.C. Wainwright initiated coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $10.00
Scotiabank initiated coverage of Perspective Therapeutics with a rating of Sector Outperform and set a new price target of $15.00
BofA Securities downgraded Perspective Therapeutics from Buy to Neutral and set a new price target of $5.00 from $24.00 previously
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
3 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)
8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
8-K - Perspective Therapeutics, Inc. (0000728387) (Filer)
Updated interim results with an additional ~16 weeks of follow-up on nine patients in Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) and initial safety findings in an additional 33 patients treated in Cohort 2 from the ongoing Phase 1/2a study were presented[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities and no discontinuations due to adverse events observed among a total of 42 patients who received at least one treatmentFour of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. Three of those patients experienced confirmed response and remained in response. One new first response is subject
Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding for [212Pb]VMT-α-NET[212Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested Three of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. First responses for two patients occurred after end of treatment period and are subject to confirmation, in addition to the previously reported patient with confirmed response who remains in response The five other patients in Coh
SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that an abstract on updated interim results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET (NCT05636618) has been accepted as a poster presentation at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI) taking place on January 23-25, 2025 in San Francisco, CA. The poster presentation entitled "Interim Safety and Efficacy data of [212Pb]VMT-α-NET in Somatostatin Receptor 2 (SSTR2) Expressing Neuroendocrine Tumors (NETs)" will
SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company's Chief Financial Officer, effective today. Mr. Sendek brings extensive experience in senior corporate roles in biotech finance and as a highly respected senior equity research analyst at a number of leading firms. Mr. Sendek previously served as CFO at four biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. He has a successful track record in corporate finance, having completed
SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that its Board of Directors has appointed Maya Martinez-Davis as an independent director to the Company's Board of Directors, effective today. Ms. Martinez-Davis currently serves as President of GSK's U.S. Commercial business, a position she has held since September 2019. In that role, she leads a robust and complex business portfolio of products in specialty, respiratory, oncology and vaccines. Prior to GSK, Ms. Martinez-Davis was President of biopharma Latin
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot
SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)
SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)
SC 13G/A - Perspective Therapeutics, Inc. (0000728387) (Subject)